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Abstract
Background: Pregnancy and parity are associated with subsequent breast cancer risk. Experimental and
epidemiologic data suggest a role for pregnancy sex steroid hormones.
Methods: We conducted a nested case–control study in the Northern Sweden Maternity Cohort (1975–2007).
Eligible women had provided a blood sample in the first 20 weeks of gestation during a primiparous pregnancy
leading to a term delivery. The current study includes 223 cases and 417 matched controls (matching factors: age
at and date of blood collection). Estrogen receptor (ER) and progesterone receptor (PR) status was available for
all cases; androgen receptor (AR) data were available for 41% of cases (n = 92). Sex steroids were quantified by
high-performance liquid chromatography tandem mass spectrometry. Odds ratios (ORs) and 95% confidence
intervals were estimated using conditional logistic regression.
Results: Higher concentrations of circulating progesterone in early pregnancy were inversely associated with
ER+/PR+ breast cancer risk (ORlog2: 0.64 (0.41–1.00)). Higher testosterone was positively associated with ER+/PR+
disease risk (ORlog2: 1.57 (1.13–2.18)). Early pregnancy estrogens were not associated with risk, except for
relatively high estradiol in the context of low progesterone (split at median, relative to low concentrations of
both; OR: 1.87 (1.11–3.16)). None of the investigated hormones were associated with ER–/PR– disease, or with
AR+ or AR+/ER+/PR+ disease.
Conclusions: Consistent with experimental models, high progesterone in early pregnancy was associated with
lower risk of ER+/PR+ breast cancer in the mother. High circulating testosterone in early pregnancy, which
likely reflects nonpregnant premenopausal exposure, was associated with higher risk of ER+/PR+ disease.
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Background
Pregnancy is associated with a transient increase in risk
of breast cancer for up to a decade post delivery, and
subsequently confers a protective effect for women
younger than 30 at first birth and for estrogen receptor
(ER) and progesterone receptor (PR) positive tumors [1].
Animal models suggest that pregnancy-associated in-
creases in estradiol and progesterone confer a protective
effect against breast cancer [2] and it is hypothesized
that higher concentrations of circulating estradiol and
progesterone during pregnancy may be associated with
the long-term decreased risk of breast cancer in women.
Endogenous sex steroid hormones and breast cancer
risk outside of pregnancy have been extensively investi-
gated in both premenopausal [3, 4] and postmenopausal
[5–7] women, with the majority of data for women post-
menopausal at blood collection. However, to date, the
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association between endogenous sex steroids in preg-
nancy and breast cancer risk in the mother has been in-
vestigated in only two populations [8–10]. Results from
the largest study to date, a case–control study nested
within the Finnish Maternity Cohort (FMC), suggest that
the association between early pregnancy endogenous
hormones and breast cancer may differ depending on age
at diagnosis. In the FMC, higher concentrations of sex
steroids were associated with higher risk among women
diagnosed at relatively young age (<40 years), and pre-
dominantly for ER–/PR– disease, while inverse associa-
tions were observed with higher estradiol concentrations
in women aged 40 years or older at diagnosis [9].
This prior study within the FMC represents the only
published data on pregnancy hormone concentrations
and breast cancer risk by hormone receptor status.
Therefore, we investigated early pregnancy endogenous
hormones and breast cancer risk in primiparous women
by hormone receptor subtype (ER, PR) using the North-
ern Sweden Maternity Cohort (NSMC). In addition, we
conducted an exploratory analysis of early pregnancy
hormones and breast cancer risk by tumor androgen re-
ceptor (AR) status; to our knowledge, this is the first in-
vestigation of early pregnancy hormones and breast
cancer risk by AR status.
Methods
The NSMC was established in 1975 and is based at the
Northern Sweden University Hospital, Umeå, Sweden.
Details of the study and case–control selection have
been published previously [11, 12]. Briefly, participants
were enrolled from the four northern counties of
Sweden while attending a maternity care unit run by the
Swedish National Health Care System. These units pro-
vide prenatal and postnatal care free of charge to all
pregnant women. Patients at these clinics provide a
blood sample during the latter part of the first trimester
or the early weeks of the second trimester to test for ru-
bella antibodies. Remaining serum is stored at −20 °C
and preserved in a central repository at the University
Hospital in Umeå. The NSMC biological bank contains
more than 150,000 serum samples from approximately
100,000 women.
To be eligible for this study, participants had to have
provided a blood sample prior to 120 gestational days of
pregnancy, during a singleton primiparous pregnancy
resulting in a term birth (gestational age (GA) at delivery
>37 to <43 weeks). Women aged 40 years or older at
sample collection or with a prior cancer diagnosis (except
nonmelanoma skin cancer) were excluded. Further, due to
changes in sample handling which may affect hormone
measurements, samples drawn after January 1, 1988 were
excluded [11]. Invasive breast cancer cases (n = 223) were
identified via linkage with the Swedish Cancer Registry;
registration of newly diagnosed cancers is based on
mandatory reporting; case ascertainment for breast cancer
is estimated to be almost 100% [13]. Details of control
selection have been published previously [12]. Briefly,
cases and controls were matched 1:2; controls (n = 417)
were selected among women alive and cancer-free (except
nonmelanoma skin cancer) at the time of diagnosis of the
corresponding case, with a blood sample available from a
singleton primiparous pregnancy resulting in a term birth,
and age < 40 years at sample collection. Controls were
matched to cases on age at blood sampling (±6 months)
and date of blood sampling (±3 months). Data on preg-
nancy and delivery characteristics were obtained from par-
ticipants’ medical records.
Laboratory assays
To ascertain hormone receptor status, all tumors were
reevaluated by one pathologist (ET) to ensure tumor inva-
siveness in the analyzed tissue block; immunohistochemi-
cal assessments were performed by two pathologists (ET,
HO). Paraffin blocks containing tumor tissue were
gathered and new sections 4 μm thick were made. Immu-
nohistochemical stains were performed on all cases using
the following primary antibodies: estrogen receptor clone
SP1, Ventana ready to use 790-4325; progesterone recep-
tor clone IE2, Ventana ready to use 790-4296; and andro-
gen receptor clone F39.4.1, Biogenex 1:50 MU256-UCE.
All stains were performed on aVentana XT platform using
locally validated protocols. Immunohistochemical stains
were evaluated as follows: brown nuclei were considered
positive regardless of staining intensity. The percentage of
positive tumor cells was registered. A cutoff value of 10%
was used to define receptor positivity.
All serum hormone assays were conducted in the De-
partment of Clinical Chemistry at Umeå University.
Samples from cases and matched controls were analyzed
in the same analytical batch alongside blinded quality
control samples (6% of total samples). Sex steroids were
quantified in two study phases (phase 1, n = 440; phase
2, n = 200) by high-performance liquid chromatography
tandem mass spectrometry on an Applied Biosystems
API4000 triple-stage quadrupole mass spectrometer. Sex
hormone binding globulin (SHBG) was quantified with a
solid-phase competitive chemiluminescence assay on an
Immulite 2000 Siemens analyzer. Free estradiol and free
testosterone were calculated using the formula of Söder-
gård et al. [14]. Intrabatch coefficients of variation (CVs)
ranged from 2% for progesterone to 16% for estrone;
interbatch CVs ranged from 3% for estradiol to 13% for
progesterone.
Statistical analyses
Hormones were log2 transformed to improve the nor-
mality of the data, and to allow for an estimation of the
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effect of a doubling of hormone concentrations. To ac-
count for differences in hormone concentrations by study
phase (concentrations presented in Additional file 1: Table
S1) we centered concentrations from each of the two
study phases at a mean of 0. Specifically, for each study
phase, we calculated the mean concentration for each hor-
mone and then subtracted this value from the observed
concentration for each study participant within that study
phase.
Hormone concentrations ≥ 3 standard deviations (SDs)
from the mean were classified as outliers. No outliers
were identified. The study population was categorized
into tertiles, based on the study phase-specific distribu-
tion in study controls. Risk associated with a doubling of
hormone concentration was assessed by modeling the
log2-transformed hormones as continuous variables; the
reported p for trend is from the model including the
continuous log2-transformed hormone concentration.
We used conditional logistic regression to estimate odds
ratios (ORs) and 95% confidence intervals (CIs). All models
controlled for GA at blood collection; this was decided a
priori given established associations between GA and hor-
mone concentrations. Further, we observed changes in the
OR of >10% comparing crude to GA-adjusted ORs for a
subset of associations. The following factors were consid-
ered as potential covariates: number of previous pregnan-
cies at blood collection (1 vs >1; includes women with
prior spontaneous or induced abortion), maternal body
mass index (BMI) at enrollment (kg/m2; continuous),
current smoking (yes/no), placental weight (g), and the ne-
onate’s birth weight (g). None of these factors changed the
OR by more than 10%; therefore, these variables were not
included in the final models. We further assessed the
impact of adjusting for estradiol, in the models evaluating
testosterone as the exposure, given that this has been
shown to attenuate testosterone–breast cancer associations
in previous studies (e.g., [6]).
We conducted analyses by hormone receptor status of
the tumor (ER+/PR+ vs ER–/PR–, AR+, AR+/ER+/PR+), as
well as analyses stratified by age at blood collection (<25 vs
≥25 years), age at diagnosis (<45 vs ≥45 years), lag-time be-
tween blood collection and diagnosis (<15 vs ≥15 years and
<20 vs ≥ 20 years), number of pregnancies at blood collec-
tion (1 vs >1), and parity at diagnosis or index date (1 vs
>1). Heterogeneity (phet) between ER+/PR+ and ER–/PR–
breast cancer subtypes was assessed using a likelihood ra-
tio test comparing models assuming the same association
between the exposures and breast cancer overall to one
assuming different associations by subtype. Interaction
was tested by including a multiplicative interaction term
in the models and evaluating the Wald p value.
All statistical tests are two-sided and considered statisti-
cally significant at p < 0.05. All analyses were conducted in
SAS 9.3 (Cary, NC, USA).
Results
Median age at blood donation in cases and controls was
26.5 (range: 17–39; matching factor; Table 1) and me-
dian GA at blood collection was approximately 10 weeks
(cases: 72 days GA; controls: 70 days). The majority of
women provided a blood sample during their first ever
pregnancy (82% of cases; 78% of controls), and were
multiparous at diagnosis or selection as a control (75%
of cases; 81% of controls).
Higher early pregnancy testosterone and SHBG were
associated with higher breast cancer risk (testosterone,
third vs first tertile OR(T3–T1): 1.46 (95% CI: 0.96–2.21),
ptrend = 0.04; SHBG: 1.68 (1.05–2.70), ptrend = 0.13)
Table 1 Maternal and child characteristics in the Northern
Sweden Maternity Cohort
Characteristic Cases (n = 223) Controls (n = 417)
Age at blood collection (years) 26.5 (17–39) 26.5 (17–39)
Gestational age at blood
collection (days)
72 (36–116) 70 (37–120)
Children at diagnosis/selection as control
1 55 (25%) 78 (19%)
2 120 (54%) 209 (50%)
3 48 (22%) 130 (31%)
Number of pregnancies at blood collectiona
1 182 (82%) 327 (78%)
2 35 (16%) 75 (18%)
3 6 (3%) 15 (4%)
Maternal weightb (kg) 61 (39–89) 60 (37–127)
Maternal heightc (cm) 165 (147–183) 165 (144–180)
Current smoker 73 (33%) 121 (29%)
Child weight (g) 3470 (2300–4680) 3450 (2115–4770)
Case characteristics
Age at diagnosis (years) 46.7 (25.5–63.8)
Lag-time (years) 19.8 (2.7–30.5)
Tumor characteristics
ER status
Positive 171 (77%)
Negative 52 (23%)
PR status
Positive 157 (70%)
Negative 66 (30%)
AR statusd
Positive 77 (84%)
Negative 15 (16%)
Data presented as median (range) or n (%)
AR androgen receptor, ER estrogen receptor, PR progesterone receptor
aNumber of pregnancies includes induced and spontaneous abortions
bMaternal weight missing for four cases
cMaternal height missing for 10 cases and 19 controls
dAR status available for 41% of cases
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(Table 2). Associations between testosterone (phet = 0.05),
free testosterone (phet < 0.01), and progesterone (phet = 0.01)
and breast cancer differed by tumor hormone receptor
status (Table 3). Testosterone and free testosterone
were positively associated with ER+/PR+ disease and
not associated with ER–/PR– disease (e.g., testosterone:
ER+/PR+ ORlog2: 1.57 (1.13–2.18); ER–/PR– ORlog2:
0.82 (0.47–1.43)). Progesterone was inversely associated
with ER+/PR+ disease (ORlog2: 0.64 (0.41–1.00)) but
not significantly associated with ER–/PR– disease
(ORlog2: 1.61 (0.77–3.36), phet = 0.01). The association
between progesterone and ER+/PR+ breast cancer was
strengthened after adjustment for circulating estradiol
concentrations (OR log2: 0.56 (0.35–0.91)).
Table 2 Early pregnancy endogenous hormones and breast cancer risk: Northern Sweden Maternity Cohort
Tertile ptrend
1 2 3
Estradiol
All women Cases/controls 68/137 70/134 82/133
OR (95% CI) Reference 1.06 (0.69–1.63) 1.29 (0.80–2.07) 0.15
ER+/PR+ Cases/controls 47/98 54/94 51/90
OR (95% CI) Reference 1.16 (0.69–1.93) 1.11 (0.62–1.97) 0.60
Free estradiol
All women Cases/controls 67/127 78/126 65/121
OR (95% CI) Reference 1.14 (0.74–1.75) 0.95 (0.59–1.54) 0.86
ER+/PR+ Cases/controls 48/90 54/83 41/85
OR (95% CI) Reference 1.13 (0.68–1.90) 0.81 (0.45–1.44) 0.72
Estrone
All women Cases/controls 63/138 81/137 78/135
OR (95% CI) Reference 1.27 (0.85–1.91) 1.25 (0.79–1.97) 0.45
ER+/PR+ Cases/controls 47/97 60/96 47/93
OR (95% CI) Reference 1.25 (0.77–2.02) 0.96 (0.55–1.65) 0.79
Testosterone
All women Cases/controls 30/137 77/136 84/134
OR (95% CI) Reference 1.29 (0.84–1.96) 1.46 (0.96–2.21) 0.04
ER+/PR+ Cases/controls 36/99 57/95 60/89
OR (95% CI) Reference 1.69 (1.00–2.86) 1.94 (1.16–3.25) 0.01
Free testosterone
All women Cases/controls 73/128 57/127 81/122
OR (95% CI) Reference 0.81 (0.52–1.25) 1.16 (0.73–1.83) 0.47
ER+/PR+ Cases/controls 44/97 41/79 59/84
OR (95% CI) Reference 1.23 (0.72–2.12) 1.68 (0.96–2.94) 0.04
Progesterone
All women Cases/controls 74/138 80/134 67/134
OR (95% CI) Reference 1.10 (0.72–1.68) 0.89 (0.56–1.40) 0.77
ER+/PR+ Cases/controls 55/84 55/99 43/99
OR (95% CI) Reference 0.75 (0.44–1.27) 0.55 (0.31–0.99) 0.05
SHBG
All women Cases/controls 59/128 67/127 86/129
OR (95% CI) Reference 1.21 (0.78–1.87) 1.68 (1.05–2.70) 0.13
ER+/PR+ Cases/controls 44/85 46/83 55/96
OR (95% CI) Reference 1.08 (0.64–1.83) 1.18 (0.67–2.08) 0.70
Conditional logistic regression controlling for gestational age at blood collection (continuous)
CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor, SHBG sex hormone binding globulin
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We cross-classified participants by circulating estradiol
and progesterone concentrations to explore the joint effects
of these hormones (i.e., estradiol/progesterone dichoto-
mized at the median: low/low, low/high, high/low, high/
high). In these models, the combination of high estradiol
and low progesterone, relative to low concentrations of
both, was associated with significantly higher risk of overall
breast cancer (overall OR: 1.87 (1.11–3.16)) (Table 4). Re-
sults for ER+/PR+ disease were similar to those observed
for overall breast cancer (ER+/PR+ OR: 1.81 (0.97–3.40);
ER–/PR– OR: 1.42 (0.43–4.64)).
We conducted exploratory analyses by tumor AR status
(AR+ and AR+/ER+/PR+); data were available for 41% of
cases. Overall, the baseline and case characteristics of
cases with and without AR status available were similar
(Additional file 1: Table S2). None of the investigated
hormones were associated with breast cancer risk when
analyses were restricted to AR+ or AR+/ER+/PR+ tumors
(Additional file 1: Table S3). The association between tes-
tosterone and ER+/PR+ disease was positive, but was at-
tenuated and not statistically significant, in the subset of
ER+/PR+ cases with AR data (all ER+/PR+ cases: n = 153,
ORlog2: 1.57 (1.13–2.18); ER+/PR+ cases with AR data:
n = 63, ORlog2: 1.32 (0.78–2.25)).
In analyses stratified by age at diagnosis, testosterone
was positively associated with risk in women with age
at diagnosis ≥ 45 years (n = 135 cases, ORlog2: 1.48
(1.06–2.05)), but not associated with risk in women di-
agnosed at age < 45 years (n = 86 cases, OR log2: 1.08
(0.68–1.71)); the difference was not statistically significant
(phet = 0.28). The association between testosterone and
breast cancer risk was strengthened after adjustment for
Table 3 Early pregnancy endogenous hormones and breast cancer risk for a doubling of hormone concentration, by ER/PR status:
Northern Sweden Maternity Cohort
Overall ER–/PR– ER+/PR+ phet
Estradiol 220/404 50/89 152/282
1.19 (0.94–1.50) 1.35 (0.78–2.32) 1.08 (0.81–1.43) 0.18
Free estradiol 210/374 49/86 143/258
1.02 (0.80–1.29) 1.09 (0.59–2.02) 0.95 (0.72–1.27) 0.31
Estrone 222/410 50/90 154/286
1.08 (0.89–1.30) 1.20 (0.77–1.88) 0.97 (0.78–1.22) 0.13
Testosterone 221/407 50/90 153/283
1.33 (1.02–1.74) 0.82 (0.47–1.43) 1.57 (1.13–2.18) 0.05
Free testosterone 211/377 49/87 144/260
1.08 (0.88–1.33) 0.66 (0.40–1.08) 1.31 (1.02–1.68) <0.01
Progesterone 221/406 50/90 153/282
0.94 (0.67–1.34) 1.61 (0.77–3.36) 0.64 (0.41–1.00) 0.01
SHBG 212/384 49/89 145/264
1.19 (0.95–1.50) 1.47 (0.90–2.40) 1.05 (0.80–1.38) 0.10
Data presented as number of cases/controls and ORlog2 (95% CI)
Conditional logistic regression controlling for gestational age at blood collection (continuous). phet between ER+/PR+ and ER–/PR– breast cancer subtypes
assessed using a likelihood ratio test comparing models assuming the same association between the hormones and breast cancer overall to one assuming
different associations by subtype
CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor, SHBG sex hormone binding globulin
Table 4 Cross-classification of early pregnancy estradiol and progesterone and breast cancer risk: Northern Sweden Maternity Cohort
Estradiol/progesterone
Low/low
(<median/<median)
Low/high
(<median/≥median)
High/low
(≥median/<median)
High/high
(≥median/≥median)
All women Cases/controls 66/141 32/59 47/56 75/145
OR (95% CI) Reference 1.14 (0.67–1.94) 1.87 (1.11–3.16) 1.10 (0.95–1.76)
ER+/PR+ Cases/controls 47/99 22/48 33/37 50/101
OR (95% CI) Reference 0.92 (0.49–1.75) 1.81 (0.97–3.40) 0.98 (0.56–1.71)
ER–/PR– Cases/controls 15/33 6/7 12/16 17/33
OR (95% CI) Reference 1.63 (0.46–5.79) 1.42 (0.43–4.64) 0.80 (0.29–2.15)
Conditional logistic regression controlling for gestational age at blood collection (continuous). Cases with reported ER+/PR– and ER–/PR+ tumors included in
analysis of “all women”
CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor
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estradiol concentrations (ER–/PR- ORlog2: 0.64 (95% CI:
0.33–1.25); ER+/PR+ ORlog2: 1.64 (1.15–2.33)).
Results stratified by age at blood collection (<25 vs
≥25 years), age at diagnosis (<45 vs ≥45 years), time
from blood collection to diagnosis (<20 vs ≥20 years),
gravidity at blood collection (1 vs >1), and parity at diag-
nosis or selection as a control (1 vs >1) were similar (data
not shown). We observed significant heterogeneity for free
testosterone when comparing associations among partici-
pants with <15 and ≥15 years between blood collection
and diagnosis (p = 0.04; n = 42 cases diagnosed < 15 years
after blood collection); however, the individual effect esti-
mates were not statistically significant (<15 years: 0.62
(0.35–1.10); ≥15 years: 1.20 (0.95–1.50)).
Discussion
We expanded the limited prior literature on endogenous
hormones in pregnancy and breast cancer risk by hor-
mone receptor status. We observed an inverse associ-
ation between early pregnancy progesterone and
subsequent risk of ER+/PR+ breast cancer. Further, we
observed positive associations between early pregnancy
testosterone and free testosterone and breast cancer,
predominantly in ER+/PR+ tumors. Early pregnancy es-
trogens alone were not associated with breast cancer,
but high estradiol in the context of low progesterone
was associated with higher risk, relative to low concen-
trations of both hormones. We observed no significant
associations between endogenous hormones and ER–/
PR– or AR+ disease.
Estrogens and progesterone increase several-fold dur-
ing pregnancy relative to prepregnant concentrations
[15, 16]; these hormones are of placental origin. Estradiol
and progesterone have well established roles in breast de-
velopment [17, 18], and data from animal models suggest
that mimicking the hormonal milieu of pregnancy with es-
tradiol and progesterone confers similar protection against
breast cancer as is conferred by pregnancy [2]. Progester-
one is essential for normal lobular–alveolar development
and differentiation in the breast [19]; our study quantified
progesterone in early pregnancy, when the breast is under-
going proliferation and the early stages of pregnancy-
associated differentiation.
Sex steroid hormones in pregnancy and breast cancer risk
in the mother have been investigated previously in three
studies nested within two populations [8–10]. Peck et al. in-
vestigated third-trimester hormones in the Child Health
and Development Study (CHDS), observing a suggestive in-
verse association between progesterone and breast cancer
risk (n = 194 cases; OR, extreme deciles: 0.49 (0.2–1.1);
ptrend = 0.08). A positive association was observed between
estrone and disease risk (OR, extreme deciles: 2.5 (1.0–6.1);
ptrend = 0.12). Pregnancy estradiol and estriol were not asso-
ciated with risk [8]. No association was observed between
early pregnancy sex steroids and overall breast cancer in
the most recent study in the FMC (n = 1199 cases) [9].
However, estradiol was positively associated with breast
cancer diagnosed before age 40 (fourth vs first quartile OR:
1.60 (1.07-2.39)) and suggestively inversely associated with
breast cancer diagnosis at age 40 years or older (fourth vs
first quartile OR: 0.71 (0.51-1.00); phet < 0.01). Associations
among women younger than age 40 years at diagnosis were
only observed for ER–/PR– tumors. In the FMC, progester-
one was associated with increased risk of ER–/PR– disease
among women diagnosed before age 40 years, but not asso-
ciated with risk among women aged 40 years or older.
In line with findings from the CHDS, we observed an
inverse association between progesterone and breast
cancer risk in the current study, although this was re-
stricted to ER+/PR+ tumors. Blood collection in the
current study was at median 10 weeks GA, in contrast
to mean of 34.5 weeks in the CHDS. Progesterone con-
centrations are modestly correlated across trimesters of
a single pregnancy (Spearman correlations: first and sec-
ond trimesters, r = 0.63; first and third trimesters, r = 0.39;
second and third trimesters, r = 0.64) [16], suggesting that
one measure in early pregnancy may not represent late
pregnancy concentrations, particularly considering first
and third trimester concentrations. Therefore, both early
pregnancy progesterone, as measured here, and late preg-
nancy progesterone, as measured in the CHDS, may im-
pact subsequent breast cancer risk.
We observed no association between estradiol and
breast cancer overall risk in the current study, with the
exception of an increased risk of disease in women with
relatively high estradiol (above median) and low proges-
terone (below median), as compared to women with low
concentrations of both hormones; this increase in risk
was evident for both hormone receptor-positive and re-
ceptor-negative disease. Experimental data from animal
models suggest that both estradiol and progesterone may
be necessary to induce the long-term protective effect of
pregnancy, although results differed based on the experi-
mental model [2, 20]. The association between breast can-
cer and cross-classified estradiol and progesterone was not
described in the previous investigations in pregnant
women, nor, to our knowledge, in epidemiologic studies in
premenopausal women. However, high concentrations of
circulating endogenous estrogens after menopause—a
period characterized by physiologically low circulating
progesterone concentrations— are consistently associated
with increased risk of breast cancer [5–7].
Given the divergent association between estradiol and
breast cancer risk in analyses stratified by age at diagnosis
in the FMC, we evaluated risk stratified by age at diagnosis
in this study (<45 vs ≥45 years). Results were similar in
both age groups for estrogens and progesterone, while
testosterone was more strongly associated with breast
Fortner et al. Breast Cancer Research  (2017) 19:82 Page 6 of 8
cancer diagnosed at age 45 years or older. Given the
age distribution in our cohort, we were unable to evalu-
ate risk using the same age thresholds as the FMC (i.e.,
only 30 cases in our population were diagnosed prior
to age 40 years). The FMC population was somewhat
older at first birth than the NSMC study population
and due to technical considerations (i.e., restriction of
the study population to women providing blood sam-
ples prior to 1988 and longer follow-up), women in the
NSMC were diagnosed at an older age (median age at
diagnosis: FMC = 41.2 years; NSMC= 46.7 years) and after
longer lag-time between pregnancy and cancer diagnosis
(median lag-time: FMC= 10.9 years; NSMC= 19.8 years).
Therefore, our findings from the NSMC may pertain to
the long-term impact of early pregnancy hormones and
breast cancer risk, whereas the FMC results may better
describe risk associated with more proximate exposure to
pregnancy hormones.
In contrast to estrogens and progesterone, androgens
increase gradually across pregnancy, approximately doub-
ling from preconception to the third trimester [15, 16]. An-
drogens are produced by the ovary and maternal adrenal
cortex as well as the adrenal glands and liver of the fetus
[21]. Androgens are relatively stable from prepregnancy to
early pregnancy, and the androgens quantified in our study
are likely representative of circulating premenopausal an-
drogen concentrations. Epidemiologic data consistently
show a positive association between androgens and breast
cancer risk, in both premenopausal [3, 4] and postmeno-
pausal [5–7] women. This may be due to a direct androgen
effect, or may be a result of conversion of androgens to
estrogens in breast tissue via aromatase; aromatase is
expressed in both normal and malignant tissue [22].
We observed higher risk of ER+/PR+ breast cancer
risk with higher circulating testosterone concentrations
in the current study. In the only prior study on andro-
gens in pregnancy and breast cancer risk, in the FMC
[9], testosterone was positively associated with risk of
ER–/PR– tumors in the subgroups of women diagnosed
younger than age 40 or with first birth younger than age
30; testosterone was not associated with breast cancer
overall or in the ER+/PR+ subgroup. As with estrogens
and progesterone, the divergent findings between the
current study and results from the FMC may be due to the
different age distributions and interval between pregnancy
and breast cancer diagnosis in the two study populations.
To our knowledge, our study is the first investigation
of early pregnancy hormones and maternal breast cancer
risk by androgen receptor status. Experimental data sug-
gest that crosstalk between the ER and AR results in im-
peded receptor signaling of both receptors, thus
inhibiting hormone-related growth and proliferation
[23]. Further, epidemiologic data show ER+/AR+ tumors
have better prognosis that ER+/AR– tumors [23]. We
observed a positive association between testosterone and
ER+/PR+ disease in all cases. The associations between
testosterone and ER+/PR+/AR+ and ER+/PR+ breast
cancer risk, among the subset of women with AR data,
were similar (among women with AR data: ER+/PR+
ORlog2: 1.32; ER+/PR+/AR+ ORlog2: 1.36), suggesting the
AR may not play an important role in this context.
Our study has important strengths and limitations.
Blood samples were collected and stored using standard-
ized procedures. However, samples are stored at a rela-
tively warm temperature (−20 °C). Estradiol and SHBG
concentrations were weakly correlated with storage time
(estradiol: r = 0.19, p < 0.01; SHBG: r = −0.20, p < 0.01),
as were free estradiol (r = 0.19, p < 0.01) and free testoster-
one (r = 0.13, p = 0.01). Cases and controls were carefully
matched for date of blood collection, therefore the weak
correlations observed between hormone concentrations
and storage time should not impact our results. Hormones
change systematically in early pregnancy with GA. We
accounted for these changes by adjusting for GA in re-
gression models. An alternative approach would be to use
regression residuals. In our study, results adjusting for GA
were similar to those using regression residuals. Finally,
sample size was limited for analyses of ER–/PR– tumors,
and AR data were only available for a subset of cases.
Conclusions
We observed an inverse association between early preg-
nancy progesterone and subsequent risk of ER+/PR+ breast
cancer as well as a positive association between early preg-
nancy testosterone and free testosterone and breast cancer,
predominantly in ER+/PR+ tumors. This investigation adds
to the limited literature on early pregnancy hormones and
breast cancer risk in the mother. As with prior studies, our
study investigated whether relatively high vs lower concen-
trations of hormones were associated with subsequent
risk of breast cancer among parous women. Further
studies investigating novel markers are necessary to
better characterize the relationship between early preg-
nancy hormones and maternal breast cancer among
this population.
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